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Abstract
Formoterol Turbuhaler has been suggested for as-needed use in asthmatic patients. We investigated whether regular treatment with
formoterol would modify the dose-response curves to formoterol in patients with partially reversible COPD. In this randomised, double-
blind, cross-over study taking place over four non-consecutive days 16 outpatients with moderate to severe COPD, who were under regular
treatment with formoterol Turbuhaler (18 mg in two daily doses) from at least 4 months, inhaled a conventional dose of formoterol
Turbuhaler 9 mg or placebo. Two hours later, a FEV1 value was established, following which a dose-response curve to formoterol
(4.5 mg/inhalation) or placebo was constructed using four inhalations (1 þ 1 þ 2)—total cumulative delivered dose of 18 mg formoterol—
with the following sequences: (1) formoterol pre-treatment þ formoterol 18 mg, (2) formoterol pre-treatment þ placebo, (3) placebo pre-
treatment þ formoterol 18 mg, (4) placebo pre-treatment þ placebo. Formoterol 9 mg induced significant (P , 0.0001) bronchodilation at
2 h after inhalation (best mean increase in FEV1: 0.170 L). Afterwards, dose-dependent increases in FEV1 occurred with formoterol
(maximum mean increase from 2-h value with formoterol: 0.072 after formoterol pre-treatment, and 0.201 L after placebo pre-treatment).
Both maximum values of bronchodilation after the last inhalation of formoterol were statistically different (P , 0.001) from 2-h levels.
These results show that dose-dependent bronchodilatation of formoterol is maintained despite regular treatment.
q 2003 Elsevier Science Ltd. All rights reserved.
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1. Introduction
The underlying bronchospasm associated with chronic
obstructive pulmonary disease (COPD) may be worsened
during acute exacerbations. As the airway obstruction
becomes more severe, the first therapeutic option is to add
an inhaled short-acting b2-agonist to give rapid relief of
bronchospasm [1]. However, since there is evidence for
down-regulation of b2-adrenoceptor protein and mRNA in
human lung tissue after selective b2-adrenoceptor agonist
treatment [2], large doses of short-acting b2-agonist may be
necessary to relieve symptoms [3,4]. The introduction of
long-acting b2-agonist bronchodilators has given physicians
additional therapeutic options for COPD [5], but the
suitability of these drugs for the treatment of acute
exacerbations in COPD is currently not known. Inhaled
formoterol and salmeterol are not normally used for
repeated inhalations in acute relief therapy [6] but recent
studies have demonstrated that formoterol can be used as
reliever medication to control asthma symptoms [7]. In fact,
formoterol has been shown to produce dose-proportional
bronchodilation in patients with partially reversible obstruc-
tive airway disease [8]. The onset of action of formoterol is
as rapid as both salbutamol and terbutaline [9–11], and a
significant effect occurs with formoterol within minutes of
inhalation of a therapeutic dose [12].
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Nonetheless, some clinicians avoid the use of formoterol
as relief medication in patients already taking it as regular
treatment. Although not seen clinically [13], it has been
suggested that there could be a greater tendency for
bronchodilator subsensitivity to develop with longer-acting
than with shorter-acting b2-agonists because of the longer
duration of b2-adrenoceptor occupancy and consequent
down-regulation. However, the development of bronchodi-
lator subsensitivity is only partial [14]. Equally, pre-
treatment with formoterol or salmeterol could reduce the
airway responses to repeated doses of another inhaled b2-
agonist. In particular salmeterol, being a partial b2-receptor
agonist, may act as a b2-antagonist in the presence of a
second b2-agonist [15].
The aim of the present study was to evaluate if there is a
potential in vivo interaction between formoterol used as
maintenance therapy and formoterol used as relief medi-
cation in patients with partially reversible COPD.
2. Methods
We assessed 16 outpatients with moderate to severe
COPD, who were in a stable phase of the disease and were
under regular treatment with formoterol Turbuhaler (18 mg
in two daily doses) from at least 4 months. All patients
reported a good compliance with formoterol before the
study. All received budesonide Turbuhaler 200 mg twice
daily in a regular manner and did not receive other
bronchodilators. Table 1 outlines the baseline character-
istics of the population studied. All patients had partially
reversible airway obstruction, confirmed at an initial
screening visit when they were required to demonstrate an
increase of FEV1 of at least 15% from baseline following
inhalation of 200 mg salbutamol. All patients fulfilled the
criteria proposed by the American Thoracic Society [1]:
i.e. they were .40 years of age, current or former smokers
(.10 pack-years) without a history of asthmatic attacks,
reporting chronic cough with or without sputum production
and/or dyspnea when walking quietly on level ground.
Patients had experienced no change in symptom severity or
treatment in the preceding 4 months, had shown no signs of
a respiratory tract infection in the month preceding or during
the trial, and had not taken oral or inhaled corticosteroids for
at least 3 months. In addition, all patients had FEV1 #65%
and FVC #70% of predicted normal after bronchodilators
had been withheld for 24 h, and a best post-bronchodilator
FEV1/FVC of less than 0.8.
Patients with allergic rhinitis, atopy, positive skin test or
with a total blood eosinophil count .400 mm23 were
excluded. Patients were also excluded if they had any
coexisting cardiovascular or lung disorder. Use of inhaled
budesonide was not discontinued, whereas inhaled short-
acting bronchodilator drugs and inhaled long-acting
bronchodilator agents, included regular formoterol Turbu-
haler, were not permitted for at least 6 and 12 h,
respectively, prior to each test. Patients were asked to
refrain from consumption of cola drinks, coffee, tea, and
from smoking, in the 12 h before and also during the
investigation.
The study was conducted according to the rules of the
declaration of Helsinki and each patient gave informed
consent to all procedures.
A flow diagram of the study is shown in Fig. 1. A
randomised, double-blind crossover design was used, and
each patient received one of the following sequences on
each of four non-consecutive days with a wash-out time of at
least 48 h between each sequence: (1) formoterol 9 mg as
initial treatment þ formoterol 18 mg, (2) formoterol 9 mg as
initial treatment þ placebo, (3) placebo as initial
treatment þ formoterol 18 mg, or (4) placebo as initial
treatment þ placebo.
Table 1








after 400 mg salbutamol (%)
Absolute increase in FEV1 30 min
after 400 mg salbutamol (L)
1 M 59 49 50 17 0.250
2 M 68 40 66 22 0.210
3 M 67 47 63 15 0.190
4 M 70 56 59 20 0.290
5 M 65 57 62 16 0.250
6 M 75 53 64 15 0.200
7 M 71 64 66 16 0.240
8 F 54 55 70 18 0.300
9 M 58 56 56 17 0.270
10 M 73 65 60 15 0.200
11 M 73 40 54 19 0.150
12 M 61 51 55 15 0.200
13 M 68 26 42 23 0.160
14 M 69 39 59 29 0.300
15 M 65 62 71 16 0.270
16 M 68 53 64 25 0.340
M. Cazzola et al. / Pulmonary Pharmacology & Therapeutics 16 (2003) 105–109106
Baseline spirometric testing was performed according to
the procedures described in the American Thoracic
Society’s 1994 Update [16]. Patients then received pre-
treatment of two inhalations of formoterol 4.5 mg/inhalation
(Oxisw, AstraZeneca, Milan, Italy) or placebo from matched
Turbuhalerw devices. Three acceptable forced expiratory
manoeuvres were performed in order to obtain two
reproducible results for FVC and FEV1. The higher of the
two FEV1 results was kept for analysis. Spirometric
measurements were repeated 2 h after the pre-treatment
inhalations.
Following the 2-h (120 min) spirometry reading, a dose-
response curve to inhaled formoterol (4.5 mg/inhalation) or
placebo was constructed using four inhalations—i.e. a total
cumulative dose of 18 mg formoterol. The four inhalations
were given in three dose increments at 20-min intervals
(single inhalations at 120 and 140 min, and two inhalations
at 160 min). FEV1/FVC measurements were made 15 min
after each dose.
Increases in functional indices from baseline and after
2 h were assessed for all sequences. The maximum FEV1
value during the dose-response curve to formoterol or
placebo was chosen as the primary outcome variable. The
study had a power of 80% to detect a difference in FEV1 of
at least 0.11 L between treatments.
Analysis of spirometric data for each treatment was
performed using Student’s t-test for paired variables. Mean
responses were also compared by multifactorial analysis of
variance (ANOVA) to establish any significant overall
effect between all four treatments. In the presence of a
significant overall ANOVA, Duncan’s multiple range
testing with 95% confidence limits was used to identify
where differences were significant. A probability level of
P , 0.05 was considered significant for all tests.
3. Results
All patients completed the 4-day study. There were no
significant differences between the baseline spirometric
values of the four treatment groups (FEV1 P ¼ 0.964;
Table 2).
Spirometry values are shown in Tables 2 and 3. Initial
administration of formoterol Turbuhaler 9 mg induced a
significant (P , 0.0001) bronchodilation 2 h after inhala-
tion (best mean increase in FEV1 0.170 L), whereas placebo
did not modify the baseline values (Fig. 2). Furthermore,
formoterol, but not placebo, elicited a dose-dependent
increase in FEV1. This response occurred after both
formoterol and placebo initial treatment. A further mean
Fig. 1. Flow diagram of the study. Formoterol Turbuhaler 4.5 mg/inhalation.
Table 2
Baseline values and changes in FEV1 2 h after placebo (P), or formoterol 9 mg Turbuhaler (F), and changes from 2 h values after four cumulative inhalations of
formoterol Turbuhaler 4.5 mg (F) or placebo (P). Values are mean (95% CI)
Baseline Mean change from baseline
after 2 h
Mean change from 2 h value after
four inhalations of F 4.5 mg or P
F þ F 1.239 (1.061–1.417) þ0.125 (0.069–0.182) þ0.072 (0.038–0.106)
F þ P 1.244 (1.044–1.444) þ0.170 (0.125–0.215) 20.058 (20.106– 2 0.010)
P þ F 1.218 (1.029–1.406) 20.019 (20.055–0.017) þ0.201 (0.155–0.246)
P þ P 1.281 (1.106–1.457) 20.011 (20.047–0.025) 20.035 (20.069– 2 0.001)
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maximum increase over the 2-h value of 0.072 L occurred in
the formoterol initial treatment group (Table 2). The
maximum value of bronchodilation induced by initial
treatment with formoterol, as measured by FEV1, was
statistically significantly different from its corresponding
baseline (P , 0.0001) and post-inhalation values
(P ¼ 0.0004). The mean difference between the highest
change in FEV1 induced by formoterol after initial treatment
with formoterol and that after placebo initial treatment was
not statistically significant (P ¼ 0.242), although the first
tended to be greater (0.037 L; 95% CI: 20.027–0.101 L)
(Fig. 2).
No patient reported adverse symptoms (palpitations or a
significant increase in heart rate) during the study.
4. Discussion
This study shows that regular treatment with formoterol
does not compromise the bronchodilator response to further
cumulative inhalations of formoterol. Patients suffering
from partially reversible COPD, who are taking formoterol
as regular maintenance therapy, can use an additional dose
of formoterol during the dose interval for the control of their
symptoms.
This conclusion conflicts with several in vitro studies that
have demonstrated interactions in contracted human bronchi
between long-acting and other b2-agonists [15,17]. How-
ever, it has been demonstrated that pre-treatment with
formoterol 24 mg (metered dose) did not alter bronchodi-
lator response to repeated doses of salbutamol in patients
suffering from partially reversible COPD [18]. The present
study seems to confirm the lack of subsensitivity after
inhalation of formoterol in patients with COPD. Apparently,
after regular dosing of formoterol, further significant
bronchodilation still occurs.
In this study, high 2-h values for FEV1 were achieved
following formoterol pre-treatment and further improve-
ments were observed with cumulative formoterol doses.
Nevertheless, the dose-response curve was relatively flat
and, consequently, there was no statistically significant
difference between the highest formoterol FEV1 after
formoterol initial inhalation and that after placebo initial
inhalation. This can probably be attributed to the high
2-h FEV1 values obtained following initial formoterol
taking, which left relatively little room for bronchodilator
improvement in response to cumulative doses of
formoterol. This was not a surprise because each patient
with COPD has his/her own optimal function, that is
regarded to be the best lung function that patients can
achieve either spontaneously or as a result of treatment.
It is conceivable that the subjects studied in this specific
clinical situation were near the top of their bronchodila-
tion response after inhalation of the first dose of
formoterol. In any case, we must highlight even though
the changes in FEV1 induced by formoterol after initial
formoterol inhalation were statistically significant, their
clinical significance may be doubtful. However, many
patients with COPD show a benefit from bronchodilator
treatment despite their relatively weak bronchodilator
response as assessed through FEV1 [19]. In fact, the
change in FEV1 following bronchodilator therapy is
poorly predictive of improved symptoms and exercise
endurance in advanced COPD [20]. We cannot exclude,
therefore, that even a small improvement in FEV1 may
be beneficial in patients suffering from COPD.
The present study has shown that a maximum effect
was already achieved after a cumulative inhalation of
formoterol 18 mg delivered dose in most patients. This
finding contrasts with a previous research, which
demonstrated that formoterol (12–36 mg metered doses)
caused a dose-dependent increase in FEV1 when
Table 3
Baseline values and changes in FVC 2 h after placebo (P), or formoterol 9 mg Turbuhaler (F), and changes from 2 h values after four cumulative inhalations of
formoterol Turbuhaler 4.5 mg (F) or placebo (P). Values are mean (95% CI)
Baseline Mean change from baseline
after 2 h
Mean change from 2 h value after
four inhalations of F 4.5 mg or P
F þ F 2.013 (1.856–2.169) 0.125 (0.057–0.193) 0.109 (20.0031–0.248)
F þ P 2.047 (1.834–2.260) 0.175 (0.063–0.287) 20.029 (20.079–0.21)
P þ F 2.028 (1.816–2.239) 20.112 (20.221– 2 0.003) 0.222 (0.151–0.294)
P þ P 2.101 (1.930–2.273) 20.026 (20.110–0.057) 20.036 (20.124–0.062)
Fig. 2. Mean dose-response curves to inhaled formoterol Turbuhaler (F)
(4.5 mg inhalation) or placebo (P) after initial treatment with formoterol
9 mg Turbuhaler (F) or placebo (P).
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administered via pMDI [8]. Both the differences in the
used inhalation devises, which influence lung deposition
and bronchodilating effect of the drug, and the individual
response to formoterol, might justify this discrepancy. In
fact, some studies suggest that when a b2 agonist is
given via Turbuhaler, only half the dose be required
compared with drug administered by pMDI [21,22]. If
this is the case also in this study, it means that
formoterol Turbuhaler 18 mg delivered dose was a higher
dose that formoterol pMDI 36 mg metered dose. In any
case, we believe that the dose of the bronchodilator is
not the true problem. As stressed before, each patient
with COPD has his/her own best function that cannot be
overcome once that it has been reached. If formoterol
Turbuhaler 18 mg has induced the maximum possible
bronchodilation in our patients, a higher dose was clearly
ineffective. However, since six out 16 patients examined
in this investigation benefited by the highest used dose of
formoterol, it is advisable to administer a cumulative
27 mg delivered dose of formoterol to patients with
COPD who are under regular treatment with formoterol
when they need additional help because of severe
dyspnea.
Further studies with a larger population are now required
to evaluate the real value and safety of adding formoterol to
patients who are under regular treatment with this long-
acting b2-agonist. Resting spirometric measurements do not
obviate the need for direct pre- and postbronchodilator
assessments of symptom alleviation, whereas uses of scales
for measurement of dyspnea such as the visual analog scale,
the baseline dyspnea index and transition dyspnea index, are
tools to relate the severity of symptoms with observed levels
of pulmonary response. They will probably help us to
establish the factual impact of adding cumulative doses of
formoterol to COPD patients.
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